When to remeasure cardiovascular risk in untreated people at low and intermediate risk: Observational study

BMJ (Online)

Volumn 346, Issue 7906, 2013, Pages

  Bell, Katy J L ^a   Hayen, Andrew ^b   Irwig, Les ^c   Takahashi, Osamu ^d,e   Ohde, Sachiko ^d   Glasziou, Paul ^a  

^a BOND UNIVERSITY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d St Luke's Life Science Institute   (Japan)

^e ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMPARATIVE STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERTENSION; JAPAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING; UNITED STATES;

ADULT; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; COHORT STUDIES; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; DISEASE PROGRESSION; EPIDEMIOLOGICAL MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSERVATION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TOKYO; UNITED STATES;

EID: 84877592151     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f1895     Document Type: Article

References (21)

1. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. NVDPA, 2012.
2. New Zealand Guideline Group. The assessment and management of cardiovascular risk. NZGG, 2003. 2009. www.nzgg.org.nz.
3. Joint British Societies. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91:v1-52.
4. Scottish Intercollegiate Guidelines Network. Risk estimation and the prevention of cardiovascular disease: a national clinical guideline. Edinburgh. SIGN, 2007. 2011. www.sign. ac.uk/pdf/sign97.pdf.
5. Task Force. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prev Rehab 2007;14(Suppl 2):E1-40.
6. World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. WHO, 2007.
7. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation 2008;117:743-53. (Pubitemid 351640675)
8. National Heart Lung and Blood Institute. National Institutes of Health. Third report of the National Cholesterol Education Program (NCEP) expert panel: detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002;106:3143-421.
9. American Heart Association. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106:388-91.
10. National Heart Lung and Blood Institute. Cardiovascular risk reduction guidelines in adults: cholesterol guideline update (ATP IV) hypertension guideline update (JNC 8) obesity guideline update (obesity 2) integrated cardiovascular risk reduction guideline. NHLBI, 2011. 2011. www.nhlbi.nih.gov/ guidelines/cvd-adult/background.htm.
11. National Vascular Disease Prevention Alliance. Guidelines for the assessment of absolute cardiovascular disease risk. NVDPA, 2009.
12. Takahashi O, Glasziou PP, Perera R, Shimbo T, Suwa J, Hiramatsu S, et al. Lipid re-screening: what is the best measure and interval? Heart 2010;96:448-52.
13. Dawber TR, Meadors GF, Moore FE. Epidemiologic approaches to heart disease: the Framingham study. Am J Public Health 1951;41:279-86.
14. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham offspring study. Am J Epidemiol 1979;110:281-90. (Pubitemid 10204328)
15. US Department of Health and Human Services, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney diseases. Diagnosis of diabetes. 2011. 2012. http://diabetes.niddk.nih.gov/dm/pubs/ diagnosis/diagnosis.pdf.
16. Cupples LA, D'Agostino RB. Section 34: some risk factors related to the annual incidence of cardiovascular disease and death in pooled repeated biennial measurements. In: Kannel WB, Wolf PA, Garrison RJ, eds. Framingham Heart Study: 30 year follow-up. Department of Health and Human Services, 1987.
17. Framingham Heart Study. 2011. www.framinghamheartstudy.org/risk/ gencardio.html#.
18. Keenan K, Hayen A, Neal B, Irwig L. Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial. BMJ 2009;338:b1492.
19. Glasziou PP, Irwig L, Heritier S, Simes J, Tonkin A, the LIPID Study Investigators. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med 2008;148:656-61. (Pubitemid 351669110)
20. Takahashi O, Glasziou PP, Perera R, Shimbo T, Fukui T. Blood pressure re-screening for healthy adults: what is the best measure and interval? J Hum Hypertension 2011; doi:10.1038/jhh.2011.72.
21. Takahashi O, Farmer AJ, Shimbo T, Fukui T, Glasziou PP. A1C to detect diabetes in healthy adults: when should we recheck? Diabetes Care 2010;33:2016-7.